Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database
- First Online:
- Cite this article as:
- Mulnier, H.E., Seaman, H.E., Raleigh, V.S. et al. Diabetologia (2008) 51: 1639. doi:10.1007/s00125-008-1076-y
- 531 Downloads
Our primary aim was to establish reliable and generalisable estimates of the risk of myocardial infarction (MI) for men and women with type 2 diabetes in the UK compared with people without diabetes. Our secondary aim was to investigate how the MI risk associated with diabetes differs between men and women.
A cohort study using the General Practice Research Database (1992–1999) was carried out, selecting 40,727 patients with type 2 diabetes and 194,913 age and sex-matched patients without diabetes. Rates of MI in men and women with and without diabetes were derived, as were hazard ratios for MI adjusted for known risk factors.
The rate of MI in men with type 2 diabetes was 19.74 (95% CI 18.83–20.69) per 1,000 person-years compared with 16.18 (95% CI 15.33–17.08) per 1,000 person-years in women with type 2 diabetes. The overall adjusted relative risk of MI in diabetes versus no diabetes was 2.13 (95% CI 2.01–2.26) in men and 2.95 (95% CI 2.75–3.17) in women and decreased with age in both sexes. Women with type 2 diabetes aged 35 to 54 years were at almost five times the risk of MI compared with women of the same age without diabetes (HR 4.86 [95% CI 2.78–8.51]).
This study has demonstrated that women with type 2 diabetes are at a much greater relative risk of MI than men even when adjusted for risk factors.
KeywordsDatabaseMyocardial infarctionPrimary careRiskRisk factorsType 2 diabetes
General Practice Research Database
Although type 2 diabetes is known to be associated with an increased risk of myocardial infarction (MI) [1–4], there is still some discussion as to whether relative risk is higher in women with diabetes than in men with diabetes [5–8] and how risk is affected by increasing age . Many published studies to date were either conducted in a population of one sex only [2, 4], included people with type 1 diabetes [3, 9, 10] (which may affect the risk by age) or were limited to those under the age of 65 [11, 12] thereby excluding a measure of risk for patients with the highest prevalence of type 2 diabetes. In addition, many studies were based on comparatively small cohorts from populations with a high underlying risk of MI [13, 14] or were selected from secondary care  and consequently more likely to have worse disease progression. All of these limitations sometimes make it inappropriate to extrapolate rates and relative risks to other populations, and in particular to primary care, where the majority of decisions for early primary prevention in diabetes are made. Even results from meta-analyses are unclear. Huxley et al. reported an increased relative risk of MI in women with type 2 diabetes compared with no diabetes, but stated that their findings were limited by the small number of studies that presented data adjusted for relevant risk factors such as smoking, obesity and hypertension . A further meta-analysis has shown an adjusted increased relative risk in women, but this was not statistically different from the increased relative risk in men .
The prevalence of diabetes is increasing [16, 17] and mortality rates in people with diabetes are continuing to rise, whereas they are decreasing in people without diabetes . Reliable and generalisable data on the risk of MI in type 2 diabetes are essential, both for professionals responsible for primary prevention in type 2 diabetes and for health economists estimating the financial burden of type 2 diabetes on future health budgets. Current risk prediction calculators have been shown to be inaccurate in diabetes because they have been based on small numbers or groups that are not wholly representative of people with diabetes [19, 20]. Others have stated that an ideal model would be based on a large-scale epidemiological study . Our primary research question was to estimate the risk of MI associated with type 2 diabetes in a large unselected cohort drawn from the UK population. Our secondary research question was to investigate how the MI risk associated with diabetes differs between men and women.
We conducted a cohort study of MI risk in men and women with and without diabetes using a large, nationwide primary care database.
The General Practice Research Database (GPRD) provides anonymised data from general practices across the UK. The GPRD is largely representative of the UK general population in terms of age and sex distribution according to a comparison with Office for National Statistics data for 1994 projected from 1991 census data . At any one time the GPRD population represents some 5% of the UK general population. In 1996, for example, 6.4% of the population in England was represented on the GPRD, compared with 5.1% in Wales, 2.8% in Scotland and 5.8% in Northern Ireland [22, 23]. The data stored on the GPRD include demographics, diagnoses and symptoms, prescriptions, hospital admission and hospital discharge information. Data on any patient’s height, weight and smoking habit are also available although with some incompleteness that varies from practice to practice. Medical diagnoses and symptoms are recorded on the database using codes. GPRD data have been shown to be of high quality and validity [23–29] and have been used extensively for epidemiological research.
We used the release of the database that was available at the University of Surrey at the time of this study and identified all men and women aged 35 to 89 on 1st January 1992 (baseline) in practices contributing research-quality data from baseline until 31st October 1999. Men and women with type 2 diabetes before baseline were identified using an algorithm based on age at diagnosis, type of treatment and other supporting evidence. Those with type 1 diabetes at any time were identified using a separate algorithm described elsewhere  and excluded from the study population. Full details of the cohort selection have been published elsewhere [30, 31]. For each patient with type 2 diabetes up to five comparison patients of the same age and sex and with no record of or treatment for diabetes at any time (i.e. before 1992 or during the follow-up period) were selected at random from the database.
Identifying MI events
To ensure only first MI events were considered, all men and women with a history of MI or coronary re-vascularisation before baseline were excluded. All individuals with a first-ever diagnostic code for MI (e.g. ‘myocardial infarction’, ‘heart attack’) after baseline were then identified from within the study population. (A full list of codes is available on request.) Algorithms were established to assess the reliability of the MI diagnosis. The diagnosis was considered ‘definite’ when an MI was recorded and the patient died within 30 days or there was evidence of first treatment within 60 days with relevant prescribing (nitrates, beta blockers, calcium channel blockers, diuretics, ACE inhibitors, low-dose aspirin [see below], antiplatelet drugs or fibrinolytic drugs) plus other supporting evidence of MI within 60 days. Such supporting evidence included codes for ischaemic heart disease, location of infarct or confirmation of MI on ECG, raised cardiac enzymes, coronary artery re-vascularisation, cardiac rehabilitation, abnormal ECG or angiogram suggesting ischaemia, or hospital discharge letter. Patients with a ‘probable’ MI had a record of MI and relevant prescribing or supporting evidence, but not both. If only an MI record was evident, these were considered ‘possible’ MI cases. To test the sensitivity of the algorithm, the GPRD records for a random sample of patients with an MI were reviewed independently by two clinicians.
Other risk factors
BMI was calculated using available height and weight recordings closest to baseline. For patients without height and weight records BMI was coded as ‘unknown’. Patient records were viewed to confirm apparent BMIs of <20 kg/m2 or >50 kg/m2. BMIs of <15 kg/m2 or >55 kg/m2 (<1% of the recorded values) were deemed unreliable and were also coded as ‘unknown’. Smoking status was also established according to the record closest to baseline and patients classified as ‘smoker’, ‘ex-smoker’, ‘non-smoker’ or ‘unknown’. GPRD smoking records may refer to the number of cigarettes smoked per day or to the smoking habit e.g. non-smoker, smoker. If the record closest to baseline indicated ‘non-smoker’ status, but a ‘smoker’ record existed earlier, the patient’s smoking status was coded as ‘ex-smoker’. Patients without records related to smoking habit were coded as ‘unknown’. Among patients with diabetes, duration of diabetes at baseline was estimated either from the date of the first diabetes record or the date of the first diabetes-related prescription, whichever was earliest. If the date of diagnosis was considered to be unreliable due to the use of an improbable or impossible date (3.2%), the average duration of diabetes within the patient’s age-group was assumed for that patient and imputed. Patients with abnormal lipids (a record for raised cholesterol or dyslipidaemia or a pharmacological treatment related to cholesterol control) before baseline were identified. All patients with a diagnosis of hypertension before baseline were also identified. All identification of MI events and co-variates was performed ‘blind’ as to whether the patient had or did not have diabetes.
Analyses were performed using Stata version 8 (Stata, College Station, TX, USA). Rates of MI were calculated for men and women with diabetes and the comparison group by age-group. Cox proportional hazards models were used to calculate HRs for MI in diabetes versus no diabetes and in men versus women both in patients with and without diabetes, stratified by age-group and adjusted for smoking, BMI, hypertension and abnormal lipids. Univariate and multivariate analyses were performed to assess the association between the risk factors and MI risk. To allow for attained age in these analyses, the date of origin was set to year of birth and the date of entry was 31 December 1991. To allow for change in age-group across the 7-year study period, all age-grouping was performed using Lexis expansion. Therefore a patient aged 64 years in 1992 who had an event at age 67 years would contribute to 1 year of follow-up in the 55- to 64-year-old age-group and to 3 years of follow-up in the 65- to 74-year-old age-group.
Sensitivity analyses were carried out to test the reliability of the MI diagnosis. As low-dose aspirin is used widely in the primary prevention of MI, the effect of including or excluding aspirin as supporting evidence was investigated. Similarly, because any patient may be thought to have had an MI but later be diagnosed with ischaemic heart disease, we tested the algorithm by including and excluding codes for ischaemic heart disease from the supporting evidence criteria.
Approval for this study was given by the GPRD Scientific and Ethical Advisory Group.
Characteristics of the study cohort at baseline and number with MI events during the study
Type 2 diabetes
Average age in 1992 (years)
Duration of diabetes (years)
MI after baseline
Number of MI events and rates per 1,000 person-years by sex and attained age-group in patients with and without type 2 diabetes
Person-years at risk
Rate per 1,000 person-years (95% CI)
Patients with type 2 diabetes
Age 35–54 years
Age 55–64 years
Age 65–74 years
Age 75–84 years
Age ≥85 years
Patients without type 2 diabetes
Age 35–54 years
Age 55–64 years
Age 65–74 years
Age 75–84 years
Age ≥85 years
HRs (95% CI) for MI in type 2 diabetes compared with no diabetes stratified by sex and attained age-group, adjusted for smoking habit, BMI, hypertension and abnormal lipids
No diabetes (n)
Age 35–54 years
Age 55–64 years
Age 65–74 years
Age ≥75 years
Rates of MI were higher in men than in women, both in type 2 diabetic patients and in the comparison group. The adjusted relative risk was higher in women than in men. Women aged 35 to 54 years with diabetes were at almost five times the risk of having an MI than their age-matched comparison group (HR 4.86 [95% CI 2.78–8.51]), while the risk among men of that age-group with diabetes was double that of the comparison group (HR 2.21 [95% CI 1.92–2.54]). When we assessed the effect of the risk factors on MI risk using univariate and multivariate analyses (data not shown), we found that no one risk factor accounted for the increased relative risk in women or the decrease in diabetes-related risk with increasing age. Stratification by duration of diabetes in 5 year bands revealed a similar relative risk pattern, with women in the youngest age-groups being at greatest relative risk. Patients with a longer duration of diabetes were at greater risk than those with short duration, but this was not significant across all the age groups.
Our examination of the effect of including or excluding aspirin as supporting evidence for a genuine first MI event revealed that all MI cases selected by aspirin prescriptions and an MI code had been prescribed aspirin for the treatment of ischaemic heart disease 60 days pre or post MI. Thus aspirin was included in the medication list to support the diagnosis of MI. The exclusion of cases with a code for MI and supporting evidence of a code for ischaemic heart disease with or without a pharmacological treatment, but no other supporting evidence (0.4% of the diabetes cohort and 0.2% of the comparison group) made no difference to the risk estimates.
This study has shown that in a cohort of people with no prior MI, men and women with type 2 diabetes in the UK are at more than twice the risk of MI than those without diabetes, a difference that remains after allowing for ageing and adjusting for BMI, smoking, hypertension and abnormal lipids. The MI risk was consistently higher in men than in women for all age-groups, both in people with and without diabetes, although the relative risk of MI associated with diabetes was much greater in women than men. Younger women with type 2 diabetes carried a relative risk of MI that was five times greater than their comparison group without diabetes. This increased relative risk in women remained even when adjusted for risk factors and corroborates the findings of Huxley et al., which showed women to be at a greater relative risk than men . This finding is consistent with our previous work on all-cause mortality and stroke in type 2 diabetes [31, 32]. We consider that the data presented here are consistent and that this pattern of increased relative risk in women is likely to be real.
The sensitivity and validity of the algorithm used to detect MI may be questioned. There was no evidence to dispute the diagnosis of MI in cases defined as definite or probable when the sample of complete GPRD records was examined. The rates of MI reported here are similar to those from other studies. For example in type 2 diabetes our rates for ages 65 to 84 years were 24.8 (95% CI 23.4–26.2) per 1,000 person-years for men and 19.3 (95% CI 18.1–20.6) per 1,000 person-years for women, compared with 32.9 (95% CI 25.2–43.0) and 22.9 (95% CI 16.7–31.2) in men and women respectively reported by McAlpine et al.  for the same age-group. Our rates were lower than those reported for diabetes in a Finnish study, where the underlying rate of MI is higher than that in the UK . Our rates for men and women aged 50 to 64 years without diabetes were very similar to those reported for Oxfordshire in 1994 to 1995  and slightly lower than those reported for Glasgow and Belfast in the late 1980s and early 1990s . These comparisons demonstrate the robustness of these data and suggest (1) that they could be used as a baseline for risk of MI prior to the implementation of recent guidelines and targets [36–38] and (2) that they could be used for risk prediction calculations in type 2 diabetes.
Unlike other studies where the general population was used for comparison, this study compared MI risk in patients with type 2 diabetes and a comparison group that remained diabetes-free throughout the follow-up period. According to Harris et al.  the average time from onset to diagnosis of type 2 diabetes has been estimated to be at least 4 to 7 years. The follow-up period of our study was up to 7 years, therefore all persons who were diagnosed in the 7 year follow-up period were excluded from the potential comparison group and consequently most patients with undiagnosed diabetes will have been excluded from the comparison group. The comparison group may still contain some patients with undiagnosed diabetes but their contribution to the risk estimates for the comparison group is likely to be minimal.
Various limitations to the data exist, which may leave the risk estimates susceptible to some residual confounding. Limitations to the data on duration of diabetes, BMI and smoking have been described previously [31, 32]. Extensive sensitivity analyses that tested the effect of including and excluding patients with unknown smoking status or BMI, as well as the effect of using status at baseline as opposed to the index date, have also been reported previously . These analyses suggested that the impact of residual confounding on the risk estimates for diabetes and no diabetes will be minimal. In brief, the effect of the unknown risk factor data may be to slightly overestimate the reported risk attributed to diabetes. We have provided the numbers with unknown data in Table 1. We believe that to disregard these data completely could produce more greatly overestimated risk estimates for diabetes. We may have missed a small number of people who were treated for hypertension before baseline and who did not have a diagnosis of hypertension. To assess hypertension in all those people with hypertensive treatment only would have been impractical for this study. In addition, we believe the numbers would have been small and would have had little impact on our findings. We have not included measures of glycaemic control, because the follow-up period was largely before laboratory standardisation of glycated haemoglobin.
This study provides an estimate of the relative risk of MI for the UK population by age and sex for patients with and without type 2 diabetes. We have demonstrated that women are at a much greater relative risk than men, even when that risk is adjusted for the most influential risk factors. Given the increasing epidemic of type 2 diabetes and the falling average age at onset, plus the increased relative risk in the younger age-groups and an attributable risk of diabetes of some eleven MI cases per 1,000 person-years, the impact on the economic burden of healthcare from diabetes will be huge. Against this background, the results from this study could be useful ways of reinforcing and informing clinical decision-making especially in primary care.
This study was funded by an unconditional research grant from the British Heart Foundation. The authors’ work was entirely independent of the funding body.
Duality of interest
H. M. Colhoun has received speaker and consultancy fees from Pfizer. All other authors declare that there is no duality of interest associated with this manuscript.